Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation

Respiration

Volumn 91, Issue 1, 2016, Pages 9-17

  Calcaianu, George ^a   Canuet, Matthieu ^a   Schuller, Armelle ^a   Enache, Irina ^b   Chaouat, Ari ^c,d   Kessler, Romain ^a  

^a HÔPITAL CIVIL   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Chronic hypoxemia; Chronic obstructive pulmonary disease; FEV 1 D LCO ratio; Pulmonary vasodilators; Severe pulmonary hypertension

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; ANTIHYPERTENSIVE AGENT; CARBON DIOXIDE; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; VASODILATOR AGENT;

ADULT; AIRWAY OBSTRUCTION; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEART CATHETERIZATION; HEART INDEX; HEMODYNAMIC PARAMETERS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG ARTERY PRESSURE; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PH; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SURVIVAL RATE; SWAN GANZ CATHETER; AGED; BLOOD; BLOOD GAS ANALYSIS; COMPLICATION; HYPERTENSION, PULMONARY; KAPLAN MEIER METHOD; LUNG DIFFUSION CAPACITY; PARTIAL PRESSURE; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY; VITAL CAPACITY;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD GAS ANALYSIS; CALCIUM CHANNEL BLOCKERS; CARBON DIOXIDE; ENDOTHELIN RECEPTOR ANTAGONISTS; EPOPROSTENOL; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PARTIAL PRESSURE; PHOSPHODIESTERASE 5 INHIBITORS; PROPORTIONAL HAZARDS MODELS; PULMONARY DIFFUSING CAPACITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASODILATOR AGENTS; VITAL CAPACITY;

EID: 84955633751     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000441304     Document Type: Article

References (25)

1. Andersen KH, Iversen M, Kjaergaard J, Mortensen J, Nielsen-Kudsk JE, Bendstrup E: Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant 2012;31:373-380.
2. Chaouat A, Bugnet A-S, Kadaoui N, Schott R, Enache I, Ducoloné A: Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189-194.
3. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C: Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995;107:1193-1198.
4. Boerrigter BG, Bogaard HJ, Trip P, Groepenhoff H, Rietema H, Holverda S: Ventilatory and cardio-circulatory exercise profiles in COPD: the role of pulmonary hypertension. Chest 2012;142:1166-1174.
5. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducoloné A: 'Natural history' of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001;164:219-224.
6. Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V: Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013;62:D109-D116.
7. Wright JL, Petty T, Thurlbeck WM: Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung 1992;170:109-124.
8. Peinado VI, Barberá JA, Abate P, Ramírez J, Roca J, Santos S: Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:1605-1611.
9. Chaouat A, Savale L, Chouaid C, Tu L, Sztrymf B, Canuet M: Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 2009;136:678-687.
10. Hurdman J, Condliffe R, Elliot CA, Swift A, Rajaram S, Davies C: Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013;41:1292-1301.
11. Rietema H, Holverda S, Bogaard HJ, Marcus JT, Smit HJ, Westerhof N: Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008;31:759-764.
12. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M: A randomized, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619-628.
13. Blanco I, Gimeno E, Munoz PA, Pizarro S, Gistau C, Rodriguez-Roisin R: Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010;181:270-278.
14. Global Initiative for Chronic Obstructive Lung Disease. http://www.goldcopd.org/uploads/users/files/GOLD-Report-2015.pdf.
15. Perez T, Garcia G, Roche N, Bautin N, Chambellan A, Chaouat A: French Pulmonary Medicine Society. Guidelines for clinical practice. Management of COPD. Update 2012: pulmonary function tests. Full length text. Rev Mal Respir 2014;31:263-294.
16. Minai OA, Fessler H, Stoller JK, Criner GJ, Scharf SM, Meli Y: Clinical characteristics and prediction of pulmonary hypertension in severe emphysema. Respir Med 2014;108:482-490.
17. Chaouat A, Naeije R, Weitzenblum E: Pulmonary hypertension in COPD. Eur Respir J 2008;32:1371-1385.
18. Valerio G, Bracciale P, Grazia D'Agostino A: Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2009;3:15-21.
19. Fossati L, Müller-Mottet S, Hasler E, Speich R, Bloch KE, Huber LC: Long-term effect of vasodilator therapy in pulmonary hypertension due to COPD: a retrospective analysis. Lung 2014;192:987-995.
20. Girard A, Jouneau S, Chabanne C, Khouatra C, Lannes M, Traclet J: Severe pulmonary hypertension associated with COPD: hemodynamic improvement with specific therapy. Respiration 2015;90:220-228.
21. Dernaika TA, Beavin M, Kinasewitz GT: Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respir Int Rev Thorac Dis 2010;79:377-382.
22. Chen X, Tang S, Liu K, Li Q, Kong H, Zeng X: Therapy in stable chronic obstructive pulmonary disease patients with pulmonary hypertension: a systematic review and meta-analysis. J Thorac Dis 2015;7:309-319.
23. Katayama Y, Higenbottam TW, Diaz de Atauri MJ, Cremona G, Akamine S, Barbera JA: Inhaled nitric oxide and arterial oxygen tension in patients with chronic obstructive pulmonary disease and severe pulmonary hypertension. Thorax 1997;52:120-124.
24. Agustí AG, Barberá JA, Roca J, Wagner PD, Guitart R, Rodriguez-Roisín R: Hypoxic pulmonary vasoconstriction and gas exchange during exercise in chronic obstructive pulmonary disease. Chest 1990;97:268-275.
25. Barberà JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R: Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996;347:436-440.